AngioDynamics Inc. (NASDAQ:ANGO) shares saw unusually-high trading volume on Friday . Approximately 132,680 shares traded hands during trading, a decline of 3% from the previous session’s volume of 137,293 shares.The stock last traded at $14.50 and had previously closed at $14.39.

ANGO has been the topic of a number of research reports. Canaccord Genuity downgraded AngioDynamics from a “buy” rating to a “hold” rating and dropped their price target for the stock from $14.50 to $13.00 in a research note on Tuesday, April 5th. Zacks Investment Research raised AngioDynamics from a “sell” rating to a “hold” rating in a research note on Monday, May 2nd. Piper Jaffray Cos. began coverage on AngioDynamics in a research note on Friday, April 8th. They set a “neutral” rating and a $12.00 price target on the stock. Finally, KeyCorp decreased their price objective on AngioDynamics from $17.00 to $16.00 and set an “overweight” rating for the company in a report on Friday, April 8th. Five analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $14.10.

The company has a 50 day moving average price of $13.21 and a 200 day moving average price of $11.91. The company’s market capitalization is $525.25 million.

AngioDynamics (NASDAQ:ANGO) last posted its earnings results on Thursday, April 7th. The company reported $0.15 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.14 by $0.01. The business earned $87.40 million during the quarter. AngioDynamics’s revenue was up .9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.12 earnings per share. On average, equities research analysts predict that AngioDynamics Inc. will post $0.56 earnings per share for the current fiscal year.

In related news, VP Charles R. Greiner sold 3,508 shares of the firm’s stock in a transaction dated Friday, May 6th. The stock was sold at an average price of $12.31, for a total value of $43,183.48. Following the sale, the vice president now directly owns 20,910 shares of the company’s stock, valued at $257,402.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Stephen A. Trowbridge sold 12,940 shares of the firm’s stock in a transaction dated Monday, April 25th. The stock was sold at an average price of $12.30, for a total value of $159,162.00. Following the completion of the sale, the senior vice president now directly owns 32,469 shares in the company, valued at $399,368.70. The disclosure for this sale can be found here.

Other hedge funds have bought and sold shares of the company. Lapides Asset Management LLC boosted its stake in AngioDynamics by 1.2% in the fourth quarter. Lapides Asset Management LLC now owns 700,500 shares of the company’s stock valued at $8,504,000 after buying an additional 8,400 shares during the last quarter. Royce & Associates LLC raised its stake in shares of AngioDynamics by 19.0% in the fourth quarter. Royce & Associates LLC now owns 640,801 shares of the company’s stock valued at $7,779,000 after buying an additional 102,098 shares during the period. Whitebox Advisors LLC bought a new stake in shares of AngioDynamics during the fourth quarter valued at approximately $1,384,000. Morgan Stanley raised its stake in shares of AngioDynamics by 6.2% in the fourth quarter. Morgan Stanley now owns 98,634 shares of the company’s stock valued at $1,198,000 after buying an additional 5,728 shares during the period. Finally, Nationwide Fund Advisors raised its stake in shares of AngioDynamics by 252.9% in the fourth quarter. Nationwide Fund Advisors now owns 88,374 shares of the company’s stock valued at $1,073,000 after buying an additional 63,332 shares during the period.

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease, and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.